Tudor Investment Corp
BBIO icon

Tudor Investment Corp’s BridgeBio Pharma BBIO Stock Holding History

Tudor Investment Corp’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.75M Buy
+77,170
New +$5.41M 0.01% 1182
2025
Q3 		– Sell
-124,068
Closed -$6.05M – 3355
2025
Q2 		$5.36M Buy
124,068
+32,736
+36% +$1.19M 0.01% 1052
2025
Q1 		$3.16M Buy
+91,332
New +$3.08M 0.01% 1048
2024
Q2 		– Sell
-22,164
Closed -$685K – 2321
2024
Q1 		$685K Buy
+22,164
New +$754K ﹤0.01% 1509
2023
Q4 		– Sell
-81,150
Closed -$2.14M – 2372
2023
Q3 		$2.14M Buy
+81,150
New +$2.3M 0.02% 895
2023
Q2 		– Sell
-23,321
Closed -$387K – 2427
2023
Q1 		$387K Sell
23,321
-51,187
-69% -$597K 0.01% 1765
2022
Q4 		$568K Sell
74,508
-5,218
-7% -$50K 0.01% 1496
2022
Q3 		$792K Buy
+79,726
New +$828K 0.02% 1075
2022
Q1 		– Sell
-120,372
Closed -$2.01M – 2008
2021
Q4 		$2.01M Buy
120,372
+29,679
+33% +$1.26M 0.03% 620
2021
Q3 		$4.25M Buy
90,693
+43,630
+93% +$2.34M 0.07% 323
2021
Q2 		$2.87M Buy
+47,063
New +$2.69M 0.05% 410

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Tudor Investment Corp's BBIO Position: Q2 2026 in Review

Tudor Investment Corp opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 77,170 shares worth $5.75M. The stake represents 0.01% of the portfolio and ranks #1182 among its holdings. This is a return to the name: Tudor Investment Corp previously reported a position in BBIO as recently as Q2 2025.

Tudor Investment Corp first reported a position in BBIO in Q2 2021 and has held it in 11 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Tudor Investment Corp held 77,170 shares of BridgeBio Pharma worth $5.75M as of Q2 2026.
  • BridgeBio Pharma was a new Tudor Investment Corp position in Q2 2026.
  • BridgeBio Pharma made up 0.01% of Tudor Investment Corp's portfolio in Q2 2026, its #1182 holding.
  • Tudor Investment Corp first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 11 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.